KeyBanc analyst Matthew Gillmor lowered the firm’s price target on HCA Healthcare (HCA) to $370 from $420 and keeps an Overweight rating on the shares. The firm says that its revised price target reflects elevated policy uncertainty under the incoming Trump administration.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target lowered to $390 from $430 at Truist
- HCA Healthcare chief ethics, compliance officer Kathi Whalen to retire
- HCA Healthcare price target lowered to $355 from $406 at Morgan Stanley
- HCA Healthcare assumed with a Neutral at JPMorgan
- Buy/Sell: Wall Street’s top 10 stock calls this week